[Studies on the predictors of response to immunosuppressive therapy in severe aplastic anemia patients]. 2009

Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.

OBJECTIVE To assay the factors that may predict the response to immunosuppressive therapy (IST) in severe aplastic anemia patients. METHODS The blood samples were collected from 37 patients diagnosed as severe aplastic anemia in West China Hospital of Sichuan University and West China Second Hospital of Sichuan University during February, 2006 to March, 2007. Twenty healthy blood donors were used as normal control. The plasma levels of IFN-gamma and IL-2 were measured by enzyme linked immunosorbent assay, and the gene phenotype of HLA-DRB1 * 15 and HLA-DRB1 * 1501 was analyzed by polymerase chain reaction with sequence specific primer. The expressions of CD55 and CD59 on the cellular membrane of red blood cell and white blood cells also were measured. RESULTS The response rate in the patients who had higher IL-2 level before IST was significantly better than that in the patients with lower IL-2 level (66.7% vs 28.6%, P<0.05), while similar result was observed to IFN-gamma (73.7% vs 25.0%, P<0.05). The response rate in the patients with positive HLA-DRB1 * 15 was higher than that in those negative patients (62.5% vs 44.4%, P>0.05), but there was no different found in different HLA-DRB1 * 1501 phenotypes (50% vs 50%, P>0.05). The response rates in the patients with deficient CD55 and CD59 expression were higher than those expressed CD55 and CD59 normally (80.0% vs 40.0%, P>0.05); the response rate of patients younger than 40 years was higher than those older than 40 years (60.0% vs 14.3%, P<0.05); the response rate in female patients was higher than male patients (62.5% vs 42.9%, P<0.05). CONCLUSIONS The concentration of IL-2, IFN-gamma before IST, and age can be used as the predicting factors to immunosuppressive therapy, while the predicting value of HLA-DRB1 * 15, HLA- DRB1 * 1501 and CD55, CD59 to the response of IST still remain unclear.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005544 Forecasting The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology. Futurology,Projections and Predictions,Future,Predictions and Projections
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
December 2016, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
January 2022, Seminars in hematology,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
January 1984, Progress in clinical and biological research,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
June 2023, Zhongguo shi yan xue ye xue za zhi,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
May 2011, Haematologica,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
November 2011, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
September 2022, Leukemia,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
February 2010, European journal of haematology,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
July 2015, Annals of hematology,
Xiao-Yan Mu, and Hong Chang, and Ting Liu, and Yu-Ping Gong, and Ting Niu, and Hui Qin, and Hong-Bing Ma, and Wen-Tong Meng
June 2018, Clinical case reports,
Copied contents to your clipboard!